×

Indications
ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone. Read more

ENBREL is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.

ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). ENBREL can be used with or without MTX.

ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ages 2 and older. Close

Our Lab Is Everywhere logo

Do you ever wonder how patients are really doing outside of office visits? Some patients document their experiences by tracking their health in a journal or a mobile app. But often, the information isn’t conveyed well or even at all during an office visit. We wanted to find a convenient way for patients to consistently collect information about key signs and symptoms and easily share it with their physicians.

See what we discovered

Our lab

Symptom tracking wises up



Supporting the patient-physician dialogue in a busy world

Many physicians spend 13–24 minutes with patients during a typical office visit. Given that time constraint, the patient-physician dialogue is usually focused on uncovering key information quickly and accurately from the patient. But that’s not always so easy. Patients’ self-reported symptoms are heavily influenced by the ones they’ve experienced most recently. This phenomenon, known as recency bias, can make the discussion around the patient’s experience unintentionally shortsighted.

Statwise supports the patient-physician dialogue to uncover key information quickly and accurately.
13–24 minutes

Mobile tracking apps can help overcome recency bias by allowing patients to see trends that occur over a longer period of time. However, when the patient uses that data to share with their doctor, it’s often very difficult for the doctor to sift through data in order to find meaningful insights.

Statwise supports the patient-physician dialogue to uncover key information quickly and accurately.
13–24 minutes



Case in point Tracking chronic conditions


Tracking rheumatoid arthritis symptoms allows patients to see tangible proof of how their treatment is working.

For most of us, days, weeks, and months often seem to blend together in our memories. We tend to recall high and low points, which can overshadow everything in between. For RA patients, this may provide a recency-biased picture of their chronic disease.


However, tracking can help RA patients more accurately recall how their symptoms may change over time.

Statwise conducted interviews with patients and rheumatologists to find an ideal solution to health tracking.

Mobile tracking apps may seem like an ideal solution, but many apps are not built for rheumatologists to easily gather meaningful insights. To learn more about their perspectives on health tracking, we conducted interviews with patients and rheumatologists.


Statwise provides visibility through self-tracking to fine-tune therapy during the first 3 months of treatment.

Both patients and rheumatologists saw self-tracking as a way to provide visibility when they're considering whether to fine-tune therapy during the first 3 months of treatment. Patients acknowledged that they’re more likely to track when they’re experiencing symptoms. Rheumatologists, on the other hand, saw value in being aware of the times when patients were feeling better too, because it gave them the opportunity to address drop-off and adherence issues.



Tracking rheumatoid arthritis

There were two pivotal hurdles we looked to clear: what key symptoms would a rheumatologist find meaningful and how could we make it simple for the patient to enter their responses? Clearly, there was an opportunity to support the patient-physician dialogue.

What’s needed is a tracking system that can help make visits more focused and efficient by providing the foundation for a discussion grounded in key information that can help encourage better dialogue.

Statwise is a tracking system for rheumatoid arthritis-Tracking pain, fatigue, morning joint stiffness, and dosing.

Bridging the gap with STATWISE

Knowing that rheumatologists need easily digestible and uniform information to give them visibility into the patient experience outside of office visits, we developed STATWISE.

STATWISE is a 12-week, text-based journaling system that captures important datapoints in an accessible format for patients to consistently use.


Text based?

After extensively researching a variety of tracking methods, ranging from mobile apps to paper-based journals and refrigerator magnets, we identified SMS texting as the ideal technology for patients to track their key symptoms to provide an accurate picture of their experience over a 3-month period.


Text based!

STATWISE makes inputting information simpler through text. There’s no need to download an app or fumble through the setup of app notifications. By only asking the user to respond to a text message, we knew we could create a system that didn’t place unnecessary burden on the patient. In fact, participants in product testing typically responded to a text in less than 2 minutes.

In a survey, many patients preferred a text-based system because the texts served as a reminder to track and were easy to interact with—even for patients who didn’t consider themselves to be tech savvy. Plus, texting is available to patients who don’t use a smartphone, making the method available to a wider group of patients.

This work should not be interpreted as an endorsement by, sponsorship by, or association with Apple Inc.

This site is intended for healthcare professionals only. If you are not a healthcare professional, please contact your doctor about ENBREL.

With no app to download or configure, patients simply respond to mobile texts that arrive at the times they may be most likely to experience symptoms.

Learn how your patients can enroll in STATWISE today

12:00 PM once daily

Moderate to severe RA patients receive a text at noon asking about their morning joint stiffness, at a time when they may have recently experienced the symptom.

6:00 PM once daily

In subsequent texts, moderate to severe RA patients are asked about their joint pain...

8:00 PM once daily

...their fatigue level...

9:00 AM once weekly

...and if they've taken their medication.

We put it on paper

A printed report tabulating the patient’s responses is mailed to the patient after the first week, and then in 2-week intervals. If a patient wants to share this information during a visit, instead of waiting as the patient loads an app and logs into their account, STATWISE provides a clear, concise report printed on a single sheet of paper. This allows rheumatologists to quickly draw on key points when discussing next steps with the patient.

A smart way to track RA symptoms

STATWISE is proof that it doesn’t always take a groundbreaking new technology to help moderate to severe RA patients—sometimes it’s just finding a need and trying to address it with a simple solution.

A smart way to track RA symptoms

STATWISE can help bridge the communication gap between patients and rheumatologists by facilitating more productive discussions during the critical first 3 months of treatment.

A smart way to track RA symptoms

The program empowers patients by giving them a more complete picture of their treatment and places them in a better position to convey how they’ve felt over a period of time. It gives patients a sense of ownership over the management of their condition.

In a survey of over 1,000 STATWISE users, 88% agreed or strongly agreed that the program improved discussions with their physician regarding their RA symptoms.

A smart way to track RA symptoms

Physicians had a favorable opinion of STATWISE because they noticed that it made office visits with patients more focused, structured, and efficient. They also saw that patients using STATWISE were more active in the management of their disease, both during and between office visits.

With better information and well-informed communication with their physicians, patients can be more confident when making decisions that affect their treatment going forward.

Statwise 8-week printed report
Statwise-No app to download, patients simply respond to mobile texts.
Statwise is a 12-week, text-based journaling system that captures important datapoints for rheumatoid arthritis patients. Statwise uses SMS texting. Statwise SMS texting is preferred by patients.
Statwise text asking about morning joint stiffness. Statwise text asking patients about their joint pain. Statwise text asking patient about their fatigue level. Statwise text asking if patient has taken ENBREL in the last week with Med Guide link. Statwise text response received when replied YES to Medication Taken question.

See what they’re saying about STATWISE

“It is really helpful to have consistent data over time. Tracking and recording how I was feeling in the moment instead of just reflecting on it once every 8 weeks with my rheumatologist has helped me think about lifestyle changes to make.”
– Patient
“I think it will help...just by using objective evidence into how they are doing.”
– Physician
ENBREL® (etanercept) logo Statwise is a 12-week, text-based journaling system that captures important datapoints for rheumatoid arthritis patients.

This work should not be interpreted as an endorsement by, sponsorship by, or association with Apple Inc.

This site is intended for healthcare professionals only. If you are not a healthcare professional, please contact your doctor about ENBREL.

Bridging the gap with STATWISE

Knowing that rheumatologists need easily digestible and uniform information to give them visibility into the patient experience outside of office visits, we developed STATWISE.

STATWISE is a 12-week, text-based journaling system that captures important datapoints in an accessible format for patients to consistently use.





Statwise uses SMS texting.

After extensively researching a variety of tracking methods, ranging from mobile apps to paper-based journals and refrigerator magnets, we identified SMS texting as the ideal technology for patients to track their key symptoms to provide an accurate picture of their experience over a 3-month period.





Statwise SMS texting is preferred by patients.

STATWISE makes inputting information simpler through text. There’s no need to download an app or fumble through the setup of app notifications. By only asking the user to respond to a text message, we knew we could create a system that didn’t place unnecessary burden on the patient. In fact, participants in product testing typically responded to a text in less than 2 minutes.

In a survey, many patients preferred a text-based system because the texts served as a reminder to track and were easy to interact with—even for patients who didn’t consider themselves to be tech savvy. Plus, texting is available to patients who don’t use a smartphone, making the method available to a wider group of patients.

With no app to download or configure, patients simply respond to mobile texts that arrive at the times they may be most likely to experience symptoms.

Learn how your patients can enroll in STATWISE today

12:00 PM once daily

Moderate to severe RA patients receive a text at noon asking about their morning joint stiffness, at a time when they may have recently experienced the symptom.

6:00 PM once daily

In subsequent texts, moderate to severe RA patients are asked about their joint pain...

8:00 PM once daily

...their fatigue level...

9:00 AM once weekly

...and if they've taken their medication.

Statwise-No app to download, patients simply respond to mobile texts. Statwise text asking about morning joint stiffness. Statwise text asking patients about their joint pain. Statwise text asking patient about their fatigue level. Statwise text asking if patient has taken ENBREL in the last week with Med Guide link. Statwise text response received when replied YES to Medication Taken question.
Statwise 8-week printed report

We put it on paper

A printed report tabulating the patient’s responses is mailed to the patient after the first week, and then in 2-week intervals. If a patient wants to share this information during a visit, instead of waiting as the patient loads an app and logs into their account, STATWISE provides a clear, concise report printed on a single sheet of paper. This allows rheumatologists to quickly draw on key points when discussing next steps with the patient.

A smart way to track RA symptoms

STATWISE is proof that it doesn’t always take a groundbreaking new technology to help moderate to severe RA patients—sometimes it’s just finding a need and trying to address it with a simple solution.

A detailed look at the Statwise 8-week printed report

STATWISE can help bridge the communication gap between patients and rheumatologists by facilitating more productive discussions during the critical first 3 months of treatment.

The program empowers patients by giving them a more complete picture of their treatment and places them in a better position to convey how they’ve felt over a period of time. It gives patients a sense of ownership over the management of their condition.

In a survey of over 1,000 STATWISE users, 88% agreed or strongly agreed that the program improved discussions with their physician regarding their RA symptoms.

See what they’re saying about STATWISE

“It is really helpful to have consistent data over time. Tracking and recording how I was feeling in the moment instead of just reflecting on it once every 8 weeks with my rheumatologist has helped me think about lifestyle changes to make.” – Patient
“I think it will help...just by using objective evidence into how they are doing.”
– Physician

Physicians had a favorable opinion of STATWISE because they noticed that it made office visits with patients more focused, structured, and efficient. They also saw that patients using STATWISE were more active in the management of their disease, both during and between office visits.

With better information and well-informed communication with their physicians, patients can be more confident when making decisions that affect their treatment going forward.

ENBREL® (etanercept) logo

We are ENBREL—our drive is enduring and our lab is everywhere

Our drive to find patient-centric solutions is enduring

Our lab

Come see where else our lab has been

Building a better button
The evolution of injection devices
Prescription Enbrel® (etanercept) is administered by injection.

Important Safety Information and Indications

SERIOUS INFECTIONS

Patients treated with ENBREL are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids or were predisposed to infection because of their underlying disease. ENBREL should not be initiated in the presence of sepsis, active infections, or allergy to ENBREL or its components. ENBREL should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: 1) Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before ENBREL use and periodically during therapy. Treatment for latent infection should be initiated prior to ENBREL use, 2) Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric antifungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness, and 3) Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with ENBREL should be carefully considered prior to initiating therapy in patients 1) with chronic or recurrent infection, 2) who have been exposed to TB, 3) who have resided or traveled in areas of endemic TB or endemic mycoses, or 4) with underlying conditions that may predispose them to infections such as advanced or poorly controlled diabetes. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ENBREL, including the possible development of TB in patients who tested negative for latent TB prior to initiating therapy.

MALIGNANCIES

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including ENBREL.

In adult clinical trials of all TNF blockers, more cases of lymphoma were seen compared to control patients. The risk of lymphoma may be up to several-fold higher in RA patients. The role of TNF blocker therapy in the development of malignancies is unknown.

Cases of acute and chronic leukemia have been reported in association with postmarketing TNF blocker use in RA and other indications. The risk of leukemia may be higher in patients with RA (approximately 2-fold) than the general population.

Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with TNF blockers, including ENBREL. Periodic skin examinations should be considered for all patients at increased risk for skin cancer.

Pediatric Patients

In patients who initiated therapy at ≤18 years of age, approximately half of the reported malignancies were lymphomas (Hodgkin’s and non-Hodgkin’s lymphoma). Other cases included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. Most of the patients were receiving concomitant immunosuppressants.

NEUROLOGIC REACTIONS

Treatment with TNF-blocking agents, including ENBREL, has been associated with rare (<0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability, and with peripheral nervous system demyelinating disorders. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with ENBREL therapy. Prescribers should exercise caution in considering the use of ENBREL in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders.

CONGESTIVE HEART FAILURE

Cases of worsening congestive heart failure (CHF) and, rarely, new-onset cases have been reported in patients taking ENBREL. Caution should be used when using ENBREL in patients with CHF. These patients should be carefully monitored.

HEMATOLOGIC REACTIONS

Rare cases of pancytopenia, including aplastic anemia, some fatal, have been reported. The causal relationship to ENBREL therapy remains unclear. Exercise caution when considering ENBREL in patients who have a previous history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs or symptoms of blood dyscrasias or infection. Consider discontinuing ENBREL if significant hematologic abnormalities are confirmed.

HEPATITIS B REACTIVATION

Reactivation of hepatitis B has been reported in patients who were previously infected with hepatitis B virus (HBV) and received concomitant TNF-blocking agents, including ENBREL. Most reports occurred in patients also taking immunosuppressive agents, which may contribute to hepatitis B reactivation. Exercise caution when considering ENBREL in these patients.

ALLERGIC REACTIONS

Allergic reactions associated with administration of ENBREL during clinical trials have been reported in <2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, administration of ENBREL should be discontinued immediately and appropriate therapy initiated.

IMMUNIZATIONS

Live vaccines should not be administered to patients on ENBREL. Pediatric patients, if possible, should be brought up to date with all immunizations prior to initiating ENBREL. In patients with exposure to varicella virus, temporarily discontinue ENBREL and consider prophylactic treatment with Varicella Zoster Immune Globulin.

AUTOIMMUNITY

Autoantibodies may develop with ENBREL, and rarely lupus-like syndrome or autoimmune hepatitis may occur. These may resolve upon withdrawal of ENBREL. Stop ENBREL if lupus-like syndrome or autoimmune hepatitis develops.

WEGENER’S GRANULOMATOSIS PATIENTS

The use of ENBREL in patients with Wegener’s granulomatosis receiving immunosuppressive agents (eg, cyclophosphamide) is not recommended.

MODERATE TO SEVERE ALCOHOLIC HEPATITIS

Based on a study of patients treated for alcoholic hepatitis, exercise caution when using ENBREL in patients with moderate to severe alcoholic hepatitis.

ADVERSE REACTIONS

The most commonly reported adverse reactions in RA clinical trials were injection site reaction and infection. In clinical trials of all other adult indications, adverse reactions were similar to those reported in RA clinical trials.

In general, the adverse reactions in pediatric patients were similar in frequency and type as those seen in adult patients. The types of infections reported in pediatric patients were generally mild and consistent with those commonly seen in the general pediatric population.

DRUG INTERACTIONS

The use of ENBREL in patients receiving concurrent cyclophosphamide therapy is not recommended. The risk of serious infection may increase with concomitant use of abatacept therapy. Concurrent therapy with ENBREL and anakinra is not recommended. Hypoglycemia has been reported following initiation of ENBREL therapy in patients receiving medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.

Please see Prescribing Information and Medication Guide.



INDICATIONS

ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone.

ENBREL is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.

ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). ENBREL can be used with or without MTX.

ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ages 2 and older.

See More Close